EGFR and myeloid sarcoma: It probably pairs core targets such as ESR1, AKT1, TP53, EGFR, and JUN to regulate endocrine resistance, ErbB signaling pathway, Hepatitis B, Progesterone-mediated oocyte maturation, and relaxin signaling pathway, which play a role in the treatment of MS.